NICE

News

NICE says no to Lynparza in prostate cancer, creates UK acce...

NICE has said it is unable to recommend NHS use of AstraZeneca's Lynparza for some patients with prostate cancer, after failing to reach an agreement on price with the drugmaker.

News

CSL Vifor plans UK launch after NICE backs rare disease drug...

UK cost-effectiveness organisation NICE has recommended routine NHS use of a recently-approved therapy for two forms of ANCA-associated vasculitis (AAV) – oral complement C5 inhibitor Tavne

Market Access

Business women studying charts and diagrams on digital tablet closeup. Business meetings concept

UK life science competitiveness indicators 2022: measuring w...

The latest life science competitiveness indicators (LSCIs

News

NICE backs AliveCor's smartphone-linked ECG for NHS use

In draft guidance, NICE has said that AliveCor's ECG recording device should be an option to check or heart disturbances in patients who take antipsychotic medicines.

Oncology

The challenges and opportunities for kidney cancer care reco...

Kidney cancer care is rapidly approaching a tipping point in the UK.

News

Towards a new understanding of cardiovascular risk in diabetes

NICE unlocks use of Amarin's Vazkepa in 425k NHS patients

Health technology assessment (HTA) agency NICE has finalised its guidance on Amarin's Vazkepa, clearing the path for GPs to start prescribing the drug in up to 425,000 NHS patients at high